ATR — AptarGroup, Inc.

Summary of Aptar's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Sales: Reported sales increased by 6% to $1 billion, setting a new quarterly record. Core sales, adjusted for currency and acquisitions, rose by 1%.
• Adjusted EBITDA: $213 million, down 3% year-over-year, with an adjusted EBITDA margin of 20.7%, compared to 22.6% in the prior year.
• Adjusted EPS: $1.42, a decrease of 15% from $1.68 in the previous year.
• Year-to-date Performance: Reported sales up 8%, core sales up 1%. Adjusted EBITDA consistent at $401 million, with adjusted EPS down 12% to $2.61.
• Free Cash Flow: Increased by $8 million to $99 million.
• Balance Sheet: Cash balance of $190 million, net debt of $1.2 billion, and a leverage ratio of 1.49x.

2. Strategic Updates and Business Highlights

• Segment Performance:
  • Pharma: Core sales increased 1%, with strong growth in consumer healthcare (up 15%) and resilience in injectables. Emergency medicine sales are expected to decline by approximately $65 million for the fiscal year.
  • Beauty: Core sales increased 1%, with strong growth in prestige fragrance but operational challenges persist.
  • Closures: Core sales up 4%, driven by strong beverage demand, particularly in bottled water.
• Innovation: Continued focus on expanding capabilities in drug formulation, regulatory support, and patient engagement. New patent applications and FDA approvals for inhaled therapies were highlighted.
• Sustainability: Recognized for leadership in sustainability, including being named a CDP supplier engagement leader and among the world's most sustainable companies.

3. Forward Guidance and Outlook

• Q3 Guidance: Adjusted EPS expected to be in the range of $1.45 to $1.53, with an effective tax rate of 22.5% to 24.5%.
• Full-Year Outlook: Continued expectation for capital investments between $260 million to $280 million and depreciation and amortization expenses between $310 million and $320 million.

4. Bad News, Challenges, or Points of Concern

• Emergency Medicine Decline: Anticipated decline in emergency medicine sales is a significant headwind, impacting overall pharma performance.
• Margin Pressure: Adjusted EBITDA margin declined due to unfavorable product mix and operational challenges, particularly in beauty and closures.
• Input Costs: Higher input costs due to geopolitical tensions, although largely offset through customer price adjustments.
• Geographic Weakness: Notable weakness in the Brazilian market affecting beauty and personal care sales.

5. Notable Q&A Insights

• Market Weakness: Acknowledgment of weakness in the Brazilian market for beauty products and ongoing operational issues in North America.
• Pharma Growth: Confidence expressed in the long-term growth potential of the pharma segment, particularly in GLP-1 therapies and biologics.
• Cost Management: Discussion on the need for disciplined execution and thoughtful resource allocation moving forward, especially in the beauty segment.
• Collaborative Framework: Introduction of a collaborative system framework for injectable therapies aimed at simplifying validation processes for customers.
• FX Impact: Q3 guidance assumes a euro to USD exchange rate of 1.14, indicating a headwind compared to Q2.

Overall, Aptar's Q2 2026 results reflect a mixed performance with strong sales growth in certain segments, ongoing challenges in others, and a cautious but optimistic outlook for the future under new leadership.